First AD

Second AD

Tahla Munir, MBChB, PhD, is a consultant hematologist at Leeds Teaching Hospitals NHS Trust and deputy chair of the United Kingdom National Cancer Research Institute Chronic Lymphocytic Leukemia Study Group, in Leeds, UK.

Presented by Tahla Munir, MBBS, this matching-adjusted indirect comparison demonstrated a significant progression-free survival advantage for zanubrutinib over fixed-duration acalabrutinib plus venetoclax in low-risk, treatment-naive chronic lymphocytic leukemia, with a 36-month PFS rate of 88.5% vs 77%, respectively.

Comparative Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Presented by Talha Munir, MBChB, PhD, this matching-adjusted indirect comparison demonstrated a significant progression-free survival advantage for zanubrutinib over fixed-duration acalabrutinib plus venetoclax in low-risk, treatment-naive chronic lymphocytic leukemia, with a 36-month progression-free survival rate of 88.5% vs 77%, respectively.

Comparative Efficacy of Zanubrutinib vs Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)